Trial · NCT03902080
Adverse events102
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 102
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | COVID-19 | Infections and infestations | Vibegron 75 Milligrams (mg) Once Daily (QD) | 22 | 553 | 22 |
| other | COVID-19 | Infections and infestations | Placebo | 17 | 551 | 17 |
| other | Urinary tract infection | Infections and infestations | Vibegron 75 Milligrams (mg) Once Daily (QD) | 14 | 553 | 15 |
| other | Urinary tract infection | Infections and infestations | Placebo | 12 | 551 | 13 |
| other | Hypertension | Vascular disorders | Vibegron 75 Milligrams (mg) Once Daily (QD) | 50 | 553 | 53 |
| other | Hypertension | Vascular disorders | Placebo | 46 | 551 | 46 |
| other | Haematuria | Renal and urinary disorders | Vibegron 75 Milligrams (mg) Once Daily (QD) | 11 | 553 | 11 |
| other | Haematuria | Renal and urinary disorders | Placebo | 14 | 551 | 15 |
| serious | Acute kidney injury | Renal and urinary disorders | Vibegron 75 Milligrams (mg) Once Daily (QD) | 1 | 553 | 1 |
| serious | Acute kidney injury | Renal and urinary disorders | Placebo | 0 | 551 | 0 |
| serious | Acute myocardial infarction | Cardiac disorders | Vibegron 75 Milligrams (mg) Once Daily (QD) | 1 | 553 | 1 |
| serious | Acute myocardial infarction | Cardiac disorders | Placebo | 2 | 551 | 2 |
| serious | Adenocarcinoma pancreas | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Vibegron 75 Milligrams (mg) Once Daily (QD) | 1 | 553 | 1 |
| serious | Adenocarcinoma pancreas | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 0 | 551 | 0 |
| serious | Atrial fibrillation | Cardiac disorders | Vibegron 75 Milligrams (mg) Once Daily (QD) | 1 | 553 | 1 |
| serious | Atrial fibrillation | Cardiac disorders | Placebo | 0 | 551 | 0 |
| serious | Basal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Vibegron 75 Milligrams (mg) Once Daily (QD) | 1 | 553 | 1 |
| serious | Basal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 0 | 551 | 0 |
| serious | Bullous erysipelas | Infections and infestations | Vibegron 75 Milligrams (mg) Once Daily (QD) | 1 | 553 | 1 |
| serious | Bullous erysipelas | Infections and infestations | Placebo | 0 | 551 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03902080/events